A Randomized, Double-blind, Placebo-controlled, Parallel, 12-week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetes Mellitus Patients With Painful Peripheral Neuropathy
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Pirenzepine (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions
- Sponsors WinSanTor
- 23 Jun 2022 Status changed from active, no longer recruiting to completed.
- 11 May 2022 Planned End Date changed from 14 May 2022 to 8 Jun 2022.
- 11 May 2022 Planned primary completion date changed from 30 Apr 2022 to 25 May 2022.